About: Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 August 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 1996 (uk) im August 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 1996 (ast) scientific article published on 01 August 1996 (en)
publication date	wds:Q71395944-7AA720A1-EF60-4BD1-8DDC-010F0F9A5568
publication date	1996-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71395944-53C5F705-6D2E-4268-8A0D-1ED94A43C728
language of work or name	English
author name string	wds:Q71395944-1DAD7DA3-0FE3-4C11-8359-BC867D9F497C wds:Q71395944-54B6D19C-D6D7-4349-8512-9FAF6E9ADBBD wds:Q71395944-601B2966-4CCE-43D0-990C-14748960529E wds:Q71395944-7D07EE65-D2D8-4E19-8064-34324833753A wds:Q71395944-C1795FF2-EF2B-4E6B-A70D-42395E7EE27B wds:Q71395944-F3A6727F-8B96-4109-949C-141BE2BB75AC wds:Q71395944-FED385FC-F9B2-4C57-A590-591A5F249D24
author name string	D M Karussis A Linde O Abramsky A Schwarz D Lehmann J M Gomori Z Meiner
rdfs:label	Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (en) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (nl)
skos:prefLabel	Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (en) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (nl)
name	Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (en) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (nl)
title	wds:Q71395944-DCD59ED9-0142-47BB-BD2D-29F8D2B8DB6E
title	Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation (en)
page(s)	wds:Q71395944-8F32CDAA-DD1B-419C-83C6-AC3926BC7B0E
page(s)	341-346
instance of	wds:Q71395944-CF5F8217-0E9F-48FB-B883-C26A3E49BFA3
instance of	scholarly article
main subject	wds:Q71395944-DA65E584-1B5E-49B1-9C96-3DE7921E4598 wds:Q71395944-E6ACADB1-8BC7-4179-9041-39B16F9A55E3
main subject	placebo secondary progressive multiple sclerosis
PubMed ID	wds:Q71395944-DDE472FD-85C9-47CE-9FA4-913C03427EE5
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8757002
PubMed ID	8757002
published in	wds:Q71395944-74D4ADFF-B0F2-4FE6-9670-168AE8027428
published in	Neurology
issue	wds:Q71395944-C8E45DAE-E396-49FA-B956-386302467E85
volume	wds:Q71395944-E33A62F6-829A-4960-8A9E-635D353BD774
issue	2
volume	47
DOI	wds:Q71395944-F0108EB7-CB27-4647-BF3D-B8B2225E98E9
DOI	http://dx.doi.org/10.1212/WNL.47.2.341
DOI	10.1212/WNL.47.2.341
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71395944
is cites work of	Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue Oral disease-modifying treatments for multiple sclerosis: the story so far. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved New and emerging disease modifying therapies for multiple sclerosis Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Efficacy and safety of laquinimod in multiple sclerosis: current status Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives MRI monitoring of MS in clinical trials Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects Immunomodulating therapeutic approaches for multiple sclerosis Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers Structural elucidation and conformational properties of the immunomodulator linomide Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis Structure-activity relationships studies of the anti-angiogenic activities of linomide Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis Immunotherapy of multiple sclerosis. Imaging outcome measures for progressive multiple sclerosis trials Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. Dissolution rate-limited absorption and complete bioavailability of roquinimex in man Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis Decade of the brain: neurological advances Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation Linomide activates the adrenocortical axis in the rat: inhibition of experimental autoimmune encephalomyelitis by linomide is not related to the increase of corticosterone Synthesis and antinephritic activities of quinoline-3-carboxamides and related compounds Linomide inhibits insulitis and modulates cytokine production in pancreatic islets in the nonobese diabetic mouse
is cites work of	wds:Q21145828-1963A6D1-23FF-4D53-973F-852821BAE514 wds:Q36317642-922A1081-E01D-4973-89AE-8EE185F1A693 wds:Q36830152-999F7594-5799-4018-8FDE-176C3EC22512 wds:Q38101003-A483B9B3-F079-4383-A153-A944B733619D wds:Q79808678-9852A12F-95F9-4723-A68D-944A1EBC5792 wds:Q34283358-1F4B6043-E57B-41A9-BF1C-486C2FDC1381 wds:Q43977414-6FCB341B-5338-4C43-B879-EE1D4C294AB1 wds:Q50637600-3F327742-A1DF-4783-84A8-3C2B0DBF9D0B wds:Q33798244-7FADEF19-00BC-4CA2-8DE5-6BB9913882F8 wds:Q36353053-5F186A5F-11B9-47E8-BA59-E5108823F888

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software